Results 211 to 220 of about 68,932 (288)

Systematic review and meta-analysis on the effect of adjuvant gonadotropin-releasing hormone agonist (GnRH-a) on pregnancy outcomes in women with endometriosis following conservative surgery. [PDF]

BMC Pregnancy Childbirth
Qing X, He L, Ma Y, Zhang Y, Zheng W.
europepmc   +1 more source

Gonadotropin-Releasing Hormone Agonist Therapy and Longitudinal Bone Mineral Density in Congenital Adrenal Hyperplasia.

J Clin Endocrinol Metab
Flokas ME, Wakim P, Kollender S, Sinaii N, Merke DP.   +4 more
europepmc   +1 more source

Gonadotropin Releasing Hormone agonist (GnRHa) during chemotherapy and post-cancer childbirths - a Nationwide population-based cohort study of 24,922 women diagnosed with cancer in Sweden. [PDF]

EClinicalMedicine
Rodriguez-Wallberg KA, Kieler H, Foukakis T, Li J, Gissler M, Oberg AS, Bergh J, Lundberg FE.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Gonadotropin-releasing hormone agonist (GnRHa) trigger – State of the art

Reproductive Biology, 2017
GnRH agonist (GnRHa) trigger for final oocyte maturation in GnRH antagonist co-treated IVF/ICSI cycles significantly reduces the risk of ovarian hyperstimulation syndrome (OHSS). GnRHa trigger followed by modifications of the standard luteal phase support (modified luteal phase support) secures fresh transfer in the majority of patients with excellent ...
Dosouto, C, Haahr, T, Humaidan, P
openaire   +4 more sources

Gonadotropin-Releasing Hormone Agonist Treatment in Sexual Precocity

Endocrine Development, 2015
Depot gonadotropin-releasing hormone (GnRH) analogs represent the first-line therapy in sexual precocity due to central precocious puberty. GnRH analogs desensitize the pituitary and account for the suppression of luteinizing hormone and follicle-stimulating hormone leading to a decrease of sex steroid levels.
Catherine, Pienkowski, Maithé, Tauber
openaire   +3 more sources

Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.

European Urology, 2020
CONTEXT Androgen deprivation therapy is the mainstay treatment of metastatic prostate cancer, achieved mainly by gonadotropin-releasing hormone (GnRH) agonists or antagonists.
M. Abufaraj, T. Iwata, S. Kimura, A. Haddad, Hashim Al-Ani, Lana Abusubaih, M. Moschini, A. Briganti, P. Karakiewicz, S. Shariat   +9 more
semanticscholar   +1 more source